Risk Factors Update Summary
- Operating losses increased significantly from $154.5 million in 2022 to $71.2 million in 2023.
- Accumulated deficit increased from $1.4 billion in 2022 to $1.9 billion in 2023.
- Potential milestone payment increased from $52.5 million to $65 million.
- Clinical trial expenses decreased from $32.4 million in 2022 to $8.0 million in 2023.
- Cash, cash equivalents, and marketable securities increased from $305 million to $423 million.
- Contract manufacturing expenses decreased from $24.1 million in 2022 to $1.7 million in 2023.
- Net operating loss carryforwards decreased from approximately $623 million to $618 million.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=744218&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.